Showing results (131-140 of 146) with videos related to
Sort By:
Pageof 15
Journal of the Royal Society of Medicine|November 18, 2024
Deriving and validating a risk prediction model for long COVID: a population-based, retrospective cohort study in ScotlandKaren Jeffrey, Vicky Hammersley, Rishma Maini, et al.The Lancet Regional Health. Europe|October 3, 2022
BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12-17 years in ScotlandIgor Rudan, Tristan Millington, Karen Antal, et al.Nature Communications|November 15, 2023
Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severityMaaike C Swets, Steven Kerr, James Scott-Brown, et al.Lancet (London, England)|October 16, 2022
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesUtkarsh Agrawal, Stuart Bedston, Colin McCowan, et al.Lancet (London, England)|April 26, 2021
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort studyEleftheria Vasileiou, Colin R Simpson, Ting Shi, et al.The Lancet. Respiratory Medicine|October 2, 2021
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort studyUtkarsh Agrawal, Srinivasa Vittal Katikireddi, Colin McCowan, et al.Plos Medicine|February 22, 2022
First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and WalesSteven Kerr, Mark Joy, Fatemeh Torabi, et al.BMJ Open|February 15, 2022
Investigating the uptake, effectiveness and safety of COVID-19 vaccines: protocol for an observational study using linked UK national dataEleftheria Vasileiou, Ting Shi, Steven Kerr, et al.Journal of Medicinal Chemistry|February 12, 2015
Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915)Hidenori Takahashi, Doris Riether, Alessandra Bartolozzi, et al.Proceedings of the National Academy of Sciences of the United States of America|July 31, 2021
GHB analogs confer neuroprotection through specific interaction with the CaMKIIα hub domainUlrike Leurs, Anders B Klein, Ethan D McSpadden, et al.Pageof 15